Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

IT & realty stocks propel gains
Thu, 17 Jan 01:30 pm

Indian equity markets strengthened further during the post noon trading session on the back of sustained buying activity across index heavyweights. Stocks from the realty, IT and oil and gas sectors are leading the pack of gainers, while those from the metal and capital goods sectors are amongst the top underperformers.

The BSE-Sensex is up by 95 points and the NSE-Nifty is trading up by 25 points. While the BSE Mid Cap is trading up by 0.09%, the BSE Small Cap index is trading up by 0.06%. The rupee is trading at 54.69 to the US dollar.

Most of the pharma stocks are trading mixed with IPCA Labs and Ajanta Pharma being among the top gainers while Shasun and Dishman Pharma are among the losers. Perrigo, a US based company, has launched betamethasone valerate foam 0.12% under 180-days exclusivity. It is the generic equivalent Luxiq foam 0.12%. As per the sources, Cipla was among the defendants and was sued by the innovator for the said product. This signifies there must be some arrangement with Cipla for supply of drug or its API. In 2005, Cipla had signed a deal with Pentech Pharma for supply of generic drugs, where the names of the drugs remained undisclosed. Pentech Pharma was later acquired by Perrigo. The brand size of Luxiq Foam 0.12% is US$ 40 m. The product belongs to GSK Plc's company, Stiefel Laboratories. The drug is indicated for the relief of corticosteroid-responsive skin conditions of the scalp or scalp psoriasis. Cipla is trading down by 1%.

Technology stocks are trading on a positive note with HCL Technologies, Mahindra Satyam and Wipro leading the gains. HCL Technologies has declared its second quarter results (the company has a June year ending) for the financial year 2012-2013 (2QFY13). The company witnessed a 3% QoQ growth in its revenues (in rupee terms). This was on the back of a 3% QoQ growth in volumes. The company reported a muted growth of 0.3% QoQ growth in software services and a 10.2% QoQ growth in infrastructure services during the quarter. The BPO segment witnessed a tepid growth of 1.1% QoQ. The company's operating margins improved to 22.6% as compared to the 22.2% in the previous quarter (quarter ended September 2012). Net profits grew by 9% QoQ during the quarter. The company has announced an interim dividend of Rs 2 per share. The company has added 39 new clients during the quarter. Attrition rates for software services declined marginally to 13.6% as compared to 13.4% in the previous quarter (September 2012). The stock is trading up by 4.8%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "IT & realty stocks propel gains". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.